Multiple pathways, such as the intrinsic pathway ... Major therapies for clotting disorders – warfarin and clopidogrel – are currently at the forefront of clinical studies for evaluation ...

Therapy decisions have gone through modifications over the past decade, from only having the oral option of warfarin, to a strong preference ... signs and symptoms of recurrent/progressive clotting, ...

As mentioned above, identifiable abnormalities of coagulation (thrombophilia), clotting and/or ... A ventilation/perfusion (V/Q) lung scan is performed early in the diagnostic pathway to differentiate ...

Events Rivaroxaban (number per 100 patient years) Warfarin (number per 100 patient ... the glycosylation of multiple vitamin K-dependent coagulation proteins. TF: Tissue factor; VKA: Vitamin ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

The researchers found that LPS can directly activate proteins in the blood that trigger clotting, which can block blood flow and damage vital organs. This process, known as the "contact pathway ...

Nature Research Intelligence Topics enable transformational understanding and discovery in research by categorising any document into meaningful, accessible topics. Read this blog to understand ...

A bioprosthetic or "tissue" valve created from cow or pig tissue usually doesn't require a blood thinner long-term, but research has shown benefits of taking a blood thinner for several months after ...

Updated results from the phase 3 XTEND-1 trial were presented at ISTH, once again comparing the therapy to patients' previous treatment with clotting factor replacement.